Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Politics

Jay Bhattacharya, prominent physician and economist, nominated by Trump for NIH director

by admin November 27, 2024
November 27, 2024
Jay Bhattacharya, prominent physician and economist, nominated by Trump for NIH director

Stanford-trained physician and economist Jay Bhattacharya has officially been nominated by President-elect Donald Trump to serve as the next director of the National Institutes of Health (NIH).

Trump made the announcement in a Truth Social post, writing: ‘I am thrilled to nominate Jay Bhattacharya, MD, PhD, to serve as Director of the National Institutes of Health. Dr. Bhattacharya will work in cooperation with Robert F. Kennedy Jr. to direct the Nation’s Medical Research, and to make important discoveries that will improve Health, and save lives.’

Bhattacharya met this week with Robert F. Kennedy Jr., who was nominated by Trump to lead the Department of Health and Human Services, which oversees the NIH and other health agencies, and impressed the former presidential candidate with his ideas to overhaul the NIH, which oversees U.S. biomedical research, according to a report by The Washington Post.

The NIH also awards funding grants to hundreds of thousands of researchers, oversees clinical trials on its Maryland campus and supports a variety of efforts to develop drugs and therapeutics.

The nominee for the NIH director must be confirmed by the Senate, which will have a Republican majority beginning in January.

Bhattacharya has called for moving the NIH’s focus toward funding more innovative research and cutting the influence of some of its longest-serving officials.

Kennedy Jr. has played a central role in choosing top health care staff and deputies for Trump’s next administration, including Johns Hopkins surgeon Marty Makary, who Trump selected to lead the Food and Drug Administration, and internal medicine physician and former Republican congressman from Florida Dave Weldon, who Trump chose to head the Centers for Disease Control and Prevention, according to the report.

Bhattacharya and Makary worked together on a blueprint for a proposed commission to investigate the nation’s coronavirus response, the report noted.

Trump’s selections of Makary, Weldon and family and emergency medicine physician Janette Nesheiwat, who the president-elect nominated to serve as surgeon general, also must be confirmed by the Senate.

Bhattacharya was a prominent critic of the federal government’s COVID-19 response during the early days of the pandemic. He co-wrote an open letter in October 2020, during Trump’s first term, that called for the government to roll back pandemic shutdowns but maintain ‘focused protections’ for vulnerable populations, such as the elderly.

The suggestion was supported by Republican lawmakers and many Americans who were critical of shutdowns and wanted to return to pre-pandemic life. However, public health experts, including then-NIH Director Francis S. Collins, criticized the proposal as premature and dangerous amid the spread of COVID-19 at a time when vaccines were not yet available.

Bhattacharya has also called for rolling back the power of some of the 27 institutes and centers that make up the NIH, arguing that some career civil servants wrongly shaped national policies at the height of the pandemic and did not allow dissenting perspectives.

He, along with other critics of the agency, have criticized former Director of the National Institute of Allergy and Infectious Diseases Anthony Fauci, who helped shape the nation’s coronavirus response during the Trump and Biden administrations before leaving the federal government in December 2022.

The NIH has also been investigated by congressional lawmakers over the pandemic response, with Republicans charging that the agency’s leaders mismanaged the response to the virus and calling for the agency to be overhauled.

Current and former NIH officials, including Fauci, have defended the agency’s response, arguing that federal leaders generally did the best that they could to address the virus.

This post appeared first on FOX NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
Legal challenges on administrative reach expected in Trump’s deregulatory scheme, experts say
next post
Biden announces cease-fire plan between Israel and Hezbollah ending 14 months of fighting

Related Posts

Experts slam ICC for quick case against Israel...

May 23, 2024

House Republicans to elect new Trump-era leadership with...

November 13, 2024

DAVID MARCUS: Trump should bring back Anno Domini...

March 31, 2025

A US judge partially blocked Trump’s election integrity...

May 3, 2025

Harris will not speak from Howard University on...

November 6, 2024

Trump eyes control of Ukraine’s nuclear plants as...

March 22, 2025

Small businesses barely survived Biden. They can’t wait...

March 14, 2025

Get to know Donald Trump’s Cabinet: Who has...

November 24, 2024

Morning Glory: Trump has the momentum, as does...

October 22, 2024

Trump, Harris neck and neck in battleground states...

October 24, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Market Maker Manipulation; Oops, They Did It Again!

      May 14, 2025
    • 50% of S&P 500 Stocks Just Turned Bullish – What Happens Next?

      May 14, 2025
    • Bullish Breadth Improvement Suggests Further Upside For Stocks

      May 14, 2025
    • Tariff Tensions Ease, Nasdaq Soars — But is SMH the Emerging Leader?

      May 14, 2025
    • Lawsuit tracker: New resistance battling Trump’s second term through onslaught of lawsuits taking aim at EOs

      May 14, 2025

    Categories

    • Business (926)
    • Investing (2,165)
    • Politics (2,682)
    • Stocks (1,008)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved